Press releaseGlobe Newswire
NervGen Pharma
NGEN · TSX
$1.43+$0.01 (+0.70%)TodayMarket closed ·
Prev close $1.42
Latest news
- Press releaseGlobe Newswire
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
- Press releaseGlobe Newswire
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Crude Oil Edges Higher; US Consumer Sentiment Falls In May
- NewsAvi Kapoor
Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
NervGen Announces Proposed Public Offering of Securities
- Press releaseGlobe Newswire
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
- Press releaseGlobe Newswire
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
- Press releaseGlobe Newswire
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
- Press releaseGlobe Newswire
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
- News
NervGen Pharma Says In Connection With The Voluntary Delisting From TSXV, The Co. Has Terminated Its Previously Announced ATM Equity Program Launched On December 19, 2025
- Press releaseGlobe Newswire
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
- Press releaseGlobe Newswire
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
- Press releaseGlobe Newswire
NervGen Pharma to Participate at Upcoming Investor Conferences
- Press releaseGlobe Newswire
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
- Press releaseGlobe Newswire
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium
- Press releaseGlobe Newswire
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
- Press releaseGlobe Newswire
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
- Press releaseGlobe Newswire
NervGen Pharma Begins Trading on Nasdaq Today
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.